|
US2016193316A1
|
|
Inducing Cellular Immune Responses to Plasmodium Falciparum Using Peptide and Nucleic Acid Compositions
|
|
JP2011139706A
|
|
Hla-binding peptide and method for using the same
|
|
EP2391635A2
|
|
Pan-dr binding polypeptides and uses thereof
|
|
US2005271676A1
|
|
Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
|
|
US2005049197A1
|
|
Induction of immune response against desired determinants
|
|
WO2005033265A2
|
|
Optimized multi-epitope constructs and uses thereof
|
|
EP1608672A2
|
|
Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
|
|
US2004157780A1
|
|
CTL inducing peptides from c-erb2 (HER-2/neu)
|
|
AU2003296330A1
|
|
Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
|
|
EP1569950A2
|
|
Plasmodium falciparum antigens and methods of use
|
|
AU2003291632A2
|
|
HLA Binding peptides and their uses
|
|
CN1711025A
|
|
Optimized multi-epitope constructs and uses thereof
|
|
WO03087126A2
|
|
Heteroclitic analogs and related methods
|
|
WO02061435A2
|
|
Subunit vaccines with a2 supermotifs
|
|
EP1455816A2
|
|
Hla class i and ii binding peptides and their uses
|
|
WO0147541A1
|
|
Optimized minigenes and peptides encoded thereby
|
|
AU2605501A
|
|
Inducing cellular immune responses to prostate cancer antigens using peptide andnucleic acid compositions
|
|
CA2393730A1
|
|
Hla class i a2 tumor associated antigen peptides and vaccine compositions
|
|
AU2088701A
|
|
Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
|
|
AU2087401A
|
|
Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
|
